Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)
Aetna to Buy Humana for $37 Billion
47:27 - Bloomberg's Francine Lacqua and Manus Cranny report on today's "Top Headlines." They speak on Bloomberg Television's "The Pulse." (Source: Bloomberg)
  • No Single Personality Can Unite Greece Now: Michaletos
  • Global Stock Market Still in Pretty Good Shape: Gilbert
  • Greek 'No' Vote Would Make Euro Exit Likely: Nakisa